Human WM35 melanoma cell line treated with trifluorothymidine(TFT) and lactimidomycin(LTM)

To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest. To find out whether drug signatures generated in human melanoma cell lines are predictive of outcome in melanoma patients, we generated trifluorothymidine(TFT) and lactimidomycin(LTM) signatures in cell lines WM35 . The expression of drug signatures were then tested by using GSSA (Gene Signature Survival Analysis) method to find out correlation with clinical outcome of melanoma patients.